Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

All Hands: Integrating a Team Approach to Risk-Benefit Individualization of Rheumatoid Arthritis and Psoriatic Arthritis Therapy

Premiere Date: Wednesday, January 27, 2021

This activity offers CE credit for:

1. Physicians (CME)
2. Nurses (CNE)
3. Pharmacists (ACPE)
4. ABIM (MOC)
5. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Thursday, January 27, 2022
Note: Credit Is No Longer Available

Faculty

Allan Gibofsky, MD, JD, MACR, FACP, FCLM (Moderator) Professor of Medicine Weill Cornell Medicine Attending Rheumatologist Co-Director, Clinic for Inflammatory Arthritis Hospital for Special Surgery New York, NY

Philip J. Mease, MD, MACR  Director, Rheumatology Clinical Research Swedish Medical Center/Providence-St. Joseph Health Clinical Professor, University of Washington School of Medicine Seattle, WA

Statement of Need

Although rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are associated with irreversible joint damage and physical disability, remission is now an achievable goal for the majority of patients, owing to advances in early diagnosis, new therapies, and improved treatment strategies.

This CME Outfitters Live and OnDemand webcast focuses on integrating a multidisciplinary approach to treating PsA and RA through case-based learning, with expert faculty discussing management strategies and how to integrate shared decision-making (SDM) into practice to facilitate appropriate treatment selection and empower patients.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Develop short- and long-term therapeutic strategies that account for risk-benefit in the management of patients with RA or PsA.
• Integrate a multidisciplinary approach in the treatment of patients with PsA.
• Incorporate SDM into the selection of appropriate treatments for patients with RA or PsA.

The following learning objectives pertain only to those requesting CNE or CPE credit:

• Describe short- and long-term therapeutic strategies for managing patients with RA and PsA.
• Integrate a multidisciplinary approach in the treatment of patients with PsA.
• Identify ways to incorporate SDM into the selection of appropriate treatments for patients with RA or PsA.

Financial Support

Supported by an educational grant from Pfizer Inc.

Target Audience

Rheumatologists, dermatologists, PAs, nurse practitioners, nurses, and pharmacists

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Enduring: 0376-0000-21-002-H01-P

Type: Knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Enduring material

Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

ABFM MOC: Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, All Hands: Integration a Teams Approach to Risk-Benefit Individualization of Rheumatoid Arthritis and Psoriatic Arthritis Therapy has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

MOC Part II CME Activity: Family Medicine

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to PAs: PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Gibofsky discloses that he serves on the advisory committee for Abbvie Inc.; Aurinia Pharmaceuticals Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a consultant for Abbvie Inc.; Acquist Therapeutics, Inc.; Amgen Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a stock shareholder (directly purchased) of ): Abbvie Inc.; Johnson & Johnson; Pfizer Inc.; and Regeneron Pharmaceuticals, Inc.

Dr. Mease reports he receives grants from AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb; Eli Lilly and Company; Galapagos, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sun Pharmaceutical Industries Inc.; and UCB, Inc. He is a consultant for AbbVie Inc.; Amgen Inc.; Boehringer Ingelheim; Bristol Myers Squibb; Eli Lilly and Company; Galapagos, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sun Pharmaceutical Industries Inc.; and UCB, Inc. He is on the speakers bureau for: AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb; Eli Lilly and Company; Genentech; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and UCB, Inc.

Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).